Topical Review: Glutamate in Neurologic Diseases

  title={Topical Review: Glutamate in Neurologic Diseases},
  author={Petra Bittigau and Chrysanthy Ikonomidou},
  journal={Journal of Child Neurology},
  pages={471 - 485}
Excitotoxicity has been implicated as a mechanism of neuronal death in acute and chronic neurologic diseases. Cerebral ischemia, head and spinal cord injury, and prolonged seizure activity are associated with excessive release of glutamate into the extracellular space and subsequent neurotoxicity. Accumulating evidence suggests that impairment of intracellular energy metabolism increases neuronal vulnerability to glutamate which, even when present at physiologic concentrations, can damage… 

Figures from this paper

Glutamate Transporter Dysfunction and Neuronal Death

This chapter summarizes the normal function of the four major glutamate transporters in the mammalian central nervous system (CNS), as well as their structure, distribution, and cellular

MicroRNA in glutamate receptor-dependent neurological diseases.

Based on the reported studies to date, modulation of miRNAs could emerge as a promising therapeutic target for a variety of neurological diseases that were discussed in this review.

Increased mitochondrial respiration maintains the mitochondrial membrane potential and promotes survival of cerebellar neurons in an endogenous model of glutamate receptor activation

It is suggested that the formation of reactive oxygen species by glutamate receptor activation is the unavoidable consequence of an increase in the mitochondrial respiration aimed to prevent Δψm collapse and neurodegeneration.

Neuroprotective effects of antiepileptic drugs.

There is a hope that AEDs will have a potential to serve as neuroprotectants not only in seizures, but perhaps, in other neurodegenerative conditions in humans as well.

Excitotoxicity in Autism

If glutamate contributes to the pathology of autism spectrum disorders, it is reasonable to suggest that agents modulating glutamate may have some utility in treatment, and numerous reports have supported roles for medications including memantine, depakote, amantadine, and antipsychotics in the treatment of these disorders.

Neuroprotective effects of some newer and potential antiepileptic drugs

There are data indicating that in spite of clear-cut neuroprotective effects of AEDs in experimental models of epilepsy, the subsequent occurrence of spontaneous seizure activity was not prevented, and there is also no significant correlation between neuroprotection in experimental ischemia and clinical data.

Cerebellar Granule Neurons are More Vulnerable to Transient Transport-Mediated Glutamate Release than to Glutamate Uptake Blockade. Correlation with Excitatory Amino Acids Levels

Results suggest that cerebellar granule neurons are more vulnerable to acute transport-mediated glutamate release than to uptake blockade, which correlates with the extracellular excitatory amino acids levels.

Pharmacology of AMPA/Kainate Receptor Ligands and Their Therapeutic Potential in Neurological and Psychiatric Disorders

Evidence for advantages of AMPA receptor antagonists over N-methyl-D-aspartate (NMDA) receptor antagonists for symptomatic treatment of neurological and psychiatric conditions, and for minimising neuronal loss occurring after acute neurological diseases, are shown in animal models.



Excitotoxicity and neurodegenerative diseases.

The concept of increased neuronal vulnerability to excitotoxic injury establishes a link between slow neuronal degeneration and excitOToxicity and suggests that glutamate antagonists may prove beneficial in the treatment of chronic neurodegenerative diseases that have been resistant to therapy.

Neurodegenerative disorders: clues from glutamate and energy metabolism.

Experimental observations suggest that disturbed energy metabolism and glutamate may be involved in neuronal death leading to abiotrophic/neurodegenerative disorders in humans and, if so, glutamate antagonists or agents that improve energy metabolism may slow the degenerative process and offer a therapeutic approach for temporarily retarding the progression of these disabling disorders.

Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?

  • M. Beal
  • Biology
    Annals of neurology
  • 1992
If defective mitochondrial energy metabolism plays a role in cell death in neurodegenerative disorders, potential therapeutic strategies would be to use excitatory amino acid antagonists or agents to bypass bioenergetic defects.

Oxidative stress, glutamate, and neurodegenerative disorders.

Two broad mechanisms--oxidative stress and excessive activation of glutamate receptors--are converging and represent sequential as well as interacting processes that provide a final common pathway for cell vulnerability in the brain.

Energy Failure, Glutamate and Neuropathology: Relevance to Neurodegenerative Disorders

Observations indicate that glutamate may be involved in slow neuronal death leading to abiotrophic disorders and suggest the use of glutamate antagonists as potential neuroprotective agents to prevent or retard neuronal damage and death in relevant regions of the brain.

A potential role for excitotoxins in the pathophysiology of spinal cord injury

Findings indicate that NMDA antagonists may be beneficial in the treatment of traumatic spinal cord injury and extend the excitotoxin concept to central nervous system trauma.

Glutamate neurotoxicity in cortical cell culture

Some neurons regularly survived brief glutamate exposure; these possibly glutamate-resistant neurons had electrophysiologic properties, including chemosensitivity to glutamate, that were grossly similar to those of the original population.

Excitotoxic mechanisms of epileptic brain damage.

It is found that the seizure-brain damage syndrome induced by cholinergic agents can be prevented by pretreatment with atropine and that the Syndrome induced by any of the above methods can be either prevented or aborted respectively by either pre- or posttreatment with diazepam.